GTBP•benzinga•
EXCLUSIVE: GT Biopharma Tells Benzinga 'Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 19, 2025 by benzinga